Inhibition of the polyamine system counteracts β-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors

PLoS One. 2014 Jun 12;9(6):e99184. doi: 10.1371/journal.pone.0099184. eCollection 2014.

Abstract

In Alzheimer's disease (AD), the β-amyloid peptide (Aβ) has been causally linked to synaptic dysfunction and cognitive impairment. Several studies have shown that N-Methyl-D-Aspartate receptors (NMDAR) activation is involved in the detrimental actions of Aβ. Polyamines, like spermidine and spermine, are positive modulators of NMDAR function and it has been shown that their levels are regulated by Aβ. In this study we show here that interruption of NMDAR modulation by polyamines through blockade of its binding site at NMDAR by arcaine (0.02 nmol/site), or inhibition of polyamine synthesis by DFMO (2.7 nmol/site), reverses Aβ25-35-induced memory impairment in mice in a novel object recognition task. Incubation of hippocampal cell cultures with Aβ25-35 (10 µM) significantly increased the nuclear accumulation of Jacob, which is a hallmark of NMDAR activation. The Aβ-induced nuclear translocation of Jacob was blocked upon application of traxoprodil (4 nM), arcaine (4 µM) or DFMO (5 µM), suggesting that activation of the polyamine binding site at NMDAR located probably at extrasynaptic sites might underlie the cognitive deficits of Aβ25-35-treated mice. Extrasynaptic NMDAR activation in primary neurons results in a stripping of synaptic contacts and simplification of neuronal cytoarchitecture. Aβ25-35 application in hippocampal primary cell cultures reduced dendritic spine density and induced alterations on spine morphology. Application of traxoprodil (4 nM), arcaine (4 µM) or DFMO (5 µM) reversed these effects of Aβ25-35. Taken together these data provide evidence that polyamine modulation of extrasynaptic NMDAR signaling might be involved in Aβ pathology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Biguanides / pharmacology
  • Binding Sites
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Dendritic Spines / drug effects
  • Dendritic Spines / pathology
  • Exploratory Behavior / drug effects
  • Hippocampus / drug effects
  • Hippocampus / pathology
  • Male
  • Memory Disorders / chemically induced*
  • Memory Disorders / drug therapy
  • Memory Disorders / pathology*
  • Mice
  • Nerve Tissue Proteins / metabolism
  • Peptide Fragments / toxicity*
  • Piperidines / pharmacology
  • Polyamines / antagonists & inhibitors*
  • Polyamines / metabolism
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • Spermidine / administration & dosage
  • Spermidine / pharmacology
  • Synapses / drug effects
  • Synapses / metabolism*

Substances

  • Amyloid beta-Peptides
  • Biguanides
  • Jacob protein, mouse
  • Nerve Tissue Proteins
  • Peptide Fragments
  • Piperidines
  • Polyamines
  • Receptors, N-Methyl-D-Aspartate
  • amyloid beta-protein (25-35)
  • arcaine
  • traxoprodil mesylate
  • Spermidine

Grants and funding

This study was supported by CNPq (306164/2010-8, 481664/2010-6, 476551/2009-9). C.F. Mello and M.A. Rubin are recipients of CNPq fellowships. G.M. Gomes is recipient of DAAD/CAPES cooperation program fellowship. M.R. Kreutz is supported by the DFG (SFB 779 TP B8), DIP grant, and the German Center for Neurodegenerative Diseases (DZNE), Location Magdeburg, Germany. A. Karpova is supported by the federal state of Saxony-Anhalt, Vorhaben: Center for Behavioral Brain Sciences (CBBS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.